ScreenerHero

ZVRAZevra Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · zevra.com
11.87USD-0.17%Mkt Cap: 704.89M $P/E: 12.76

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platf…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap704.89M $
Enterprise Value486.00M $
Revenue (TTM)136.07M $
Gross Profit89.99M $
Net Income (TTM)83.23M $
Revenue/Share2.367 USD
Last Price11.87 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees61
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)12.76
P/E (Forward)11.32
PEG10.67
EV/EBITDA11.98
EV/Revenue3.57
P/S5.19
P/B3.42
EPS (TTM)0.91
EPS (Forward)1.05
52W Range
7.16060% of range14.96
52W High14.96 USD
52W Low7.160 USD
Profitability
Gross Margin84.52%
Oper. Margin42.30%
EBITDA Margin29.80%
Profit Margin78.17%
ROE53.82%
ROA29.23%
Growth
Revenue Growth53.30%
Earnings Growth-88.40%
Cash Flow & Leverage
Operating CF-1.60M $
CapEx (TTM)835.00K $
FCF Margin35.56%
FCF Yield6.86%
Net Debt-220.07M $
Net Debt/EBITDA-5.43
Balance Sheet
Debt/Equity0.41
Current Ratio5.17
Quick Ratio5.02
Book Value/Sh3.481 USD
Cash/Share3.731 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 28, 2020
Splits
Last Split1:16
Split DateDec 28, 2020
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)25.00 USD
Upside (mean)+110.6%
Target Range20.00 USD – 35.00 USD
$20.00+110.6% to mean$35.00
# Analysts9
Ownership
Shares Out.59.38M
Float53.90M
Insiders1.26%
Institutions77.15%
Short Interest
Short Ratio4.6d
Short % Float12.15%
Short % Out.12.01%
Shares Short7.13M
Short (prev mo.)6.49M
Technical
SMA 5012.24 (-3.0%)
SMA 20010.14 (+17.0%)
Beta0.92
S&P 52W Chg18.16%
Avg Vol (30d)1.27M
Avg Vol (10d)876.99K
Technical Indicators
RSI (14)54.0
MACD-0.0138
MACD Signal-0.2020
MACD Hist.+0.1882
BB Upper12.70 USD
BB Middle10.83 USD
BB Lower8.959 USD
BB Width34.57%
ATR (14)0.5630 USD
Vol Ratio (20d)0.49x